Prospective Multicentre Study on the Epidemiology and Current Therapeutic Management of Severe Bronchiolitis in Spain

Table 5

Antibiotic treatment of patients included in the BRUCIP study.

Factors analysed		Duration (days)	Antibiotic and	Indication
Antibiotic therapy	124	5 (IQR: 4–7)	No antibiotic: 101 (39.1%); Cefotaxime: 84 (32%); Amoxicillin-clavulanic acid: 30 (11.6%); Macrolides: 18 (9.5%); Ampicillin: 13 (5%); Ceftriaxone: 3 (1.2%); Piperacillin-tazobactam: 4 (1.6%); Meropenem: 2 (0.8%); Vancomycin: 5 (2%); Others: 9 (3.5%)	Clinical: 16 (11%); Analytical: 30 (20.5%); Radiological: 14 (9.6%); Mix: 69 (47.3%); Others: 17 (11.6%)